5-Amino-1MQ
NNMT Inhibition & NAD+ Preservation (Preclinical — Mouse Models Only)
5-Amino-1MQ — Nicotinamide N-Methyltransferase (NNMT) Inhibitor
Last reviewed: August 2026
5-Amino-1MQ is a small molecule (not a peptide) that blocks an enzyme called NNMT — essentially releasing a metabolic brake that keeps fat cells in storage mode. In animal studies, it reversed obesity without any change in food intake, making it one of the most mechanistically interesting metabolic research compounds in the current literature.
NNMT is an enzyme that is overactive in obese fat tissue. When it runs too fast, it drains the body's methyl pool and diverts a key NAD+ building block away from energy metabolism. 5-Amino-1MQ blocks NNMT, which preserves NAD+ levels and activates SIRT1 — a longevity-associated enzyme that tells fat cells to burn fat instead of store it.
Most fat loss interventions work by suppressing appetite (GLP-1 agonists, stimulants) or increasing energy expenditure through stimulation. 5-Amino-1MQ works differently: it reprograms the metabolic behavior of fat cells themselves at the NAD+ and epigenetic level. In the key 2018 mouse study, obese mice lost significant fat mass in 11 days without eating less — a result with no parallel in appetite-based interventions.
5-Amino-1MQ has a well-characterized molecular mechanism, strong animal study data, and a compelling differentiated profile versus GLP-1 agonists. No human clinical trials have been completed as of 2026. It remains a research compound with significant scientific interest.
What is 5-Amino-1MQ?
5-Amino-1MQ (5-amino-1-methylquinolinium) is a selective small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that plays a central role in cellular methylation balance, NAD+ precursor availability, and adipose tissue metabolism. Unlike most compounds in the peptide research space, 5-Amino-1MQ is not a peptide — it is a quinolinium-based small molecule with a molecular weight of 174.20 Da.
NNMT is overexpressed in white adipose tissue in obese individuals, where it consumes S-adenosylmethionine (SAM) — the body's primary methyl donor — to methylate nicotinamide, effectively draining the methyl pool and reducing NAD+ precursor availability. By selectively inhibiting NNMT, 5-Amino-1MQ preserves SAM and NAD+ precursors, creating a metabolic environment that favors fat oxidation over fat storage. In the pivotal 2018 animal study by Neelakantan et al., systemic treatment with 5-Amino-1MQ reversed diet-induced obesity in mice within 11 days without any reduction in food intake.
- 5-Amino-1MQ (5-amino-1-methylquinolinium, MW 174.20 Da) is a selective small-molecule inhibitor of NNMT (nicotinamide N-methyltransferase) — it is a small molecule, not a peptide.
- Primary mechanism: inhibits NNMT to preserve SAM (the cellular methyl donor) and redirect nicotinamide into NAD+ synthesis, elevating cellular NAD+ and activating SIRT1-mediated fat oxidation.
- Pivotal 2018 study (Neelakantan et al.): reversed diet-induced obesity in mice at 20 mg/kg over 11 days without reducing food intake — fat loss was purely metabolic, not appetite-mediated.
- Distinct from GLP-1 agonists: does not suppress appetite or act on the gut-brain axis. Works specifically on adipose tissue metabolism through NAD+ and epigenetic mechanisms.
- No completed human clinical trials as of 2026; all efficacy data is from animal models. Research-only compound.
Molecular Composition
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule with the molecular formula C10H10N2 and molecular weight of 174.20 Da. It is structurally derived from the quinolinium scaffold — a bicyclic aromatic system — with an amino group at the 5-position and a methyl group at the 1-position nitrogen. This specific substitution pattern confers high selectivity for NNMT over related methyltransferase enzymes.
The compound is membrane-permeable, allowing it to enter cells and access intracellular NNMT without requiring specialized delivery systems. It is supplied as a lyophilized powder at ≥99% purity, verified by independent third-party certificate of analysis.
How Does It Work?
5-Amino-1MQ blocks NNMT to preserve NAD+ precursors and redirect adipose tissue metabolism away from fat storage toward fat oxidation — without affecting appetite.
5-Amino-1MQ inhibits NNMT (nicotinamide N-methyltransferase), an enzyme that catalyzes the N-methylation of nicotinamide using S-adenosylmethionine (SAM) as the methyl donor, producing 1-methylnicotinamide (MNA) and S-adenosylhomocysteine (SAH) as products.
In metabolically dysregulated adipose tissue, NNMT is overexpressed and consumes large quantities of SAM. This creates two downstream problems: (1) SAM depletion reduces the availability of methyl groups for other critical methylation reactions, including DNA and histone methylation; and (2) nicotinamide — a NAD+ precursor — is diverted away from the NAD+ synthesis pathway into the methylation pathway, reducing cellular NAD+ levels.
By inhibiting NNMT, 5-Amino-1MQ: (1) Preserves SAM, restoring methylation capacity for epigenetic regulation; (2) Redirects nicotinamide back into the NAD+ synthesis pathway, elevating cellular NAD+ levels; (3) Activates SIRT1 (a NAD+-dependent deacetylase), which promotes fatty acid oxidation and inhibits adipogenesis; (4) Reduces adipocyte size and white adipose tissue mass without affecting food intake.
This mechanism is distinct from GLP-1 receptor agonists (which suppress appetite) and from stimulants (which increase energy expenditure through sympathomimetic effects). 5-Amino-1MQ works specifically on the metabolic programming of adipose tissue at the epigenetic and NAD+ metabolism level.
Key Research Pathways
NNMT Inhibition / SAM Preservation
Selectively inhibits nicotinamide N-methyltransferase, preventing the consumption of S-adenosylmethionine (SAM) and preserving the cellular methyl pool for DNA methylation, histone methylation, and other critical epigenetic processes.
NAD+ Precursor Redirection
By blocking NNMT-mediated nicotinamide methylation, 5-Amino-1MQ redirects nicotinamide back into the NAD+ biosynthesis pathway (via NAMPT), elevating cellular NAD+ levels and activating NAD+-dependent enzymes including sirtuins.
SIRT1 Activation / Fatty Acid Oxidation
Elevated NAD+ activates SIRT1 (Sirtuin 1), a NAD+-dependent deacetylase that promotes fatty acid oxidation, inhibits adipogenesis, and improves insulin sensitivity — producing the metabolic reprogramming observed in animal studies.
Adipocyte Size Reduction / White Adipose Remodeling
NNMT inhibition reduces adipocyte hypertrophy and promotes a shift from lipid storage to lipid oxidation in white adipose tissue, directly reducing fat mass without appetite suppression.
Key Findings from the Literature
- Reversed diet-induced obesity in mice within 11 days at 20 mg/kg without reducing food intake (Neelakantan et al., 2018)
- Concentration-dependent NNMT inhibition in fully differentiated adipocytes confirmed in vitro (Neelakantan et al., 2018)
- Combined with low-fat diet: dramatic whole-body adiposity reduction and metabolic normalization (Kannt et al., 2022)
- Preserves NAD+ precursor availability and activates SIRT1-mediated fatty acid oxidation
- High membrane permeability enables intracellular NNMT access without specialized delivery systems
Important Research Context
Research References
Peer-reviewed literature supporting the research profile of 5-Amino-1MQ
The following peer-reviewed studies form the primary evidence base for 5-Amino-1MQ's research profile. All references are sourced from PubMed, NCBI, and peer-reviewed scientific journals. Published research is available through PubMed, NCBI, and peer-reviewed biomedical journals.
- 1.
Neelakantan H, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice. Biochemical Pharmacology. 2018.PMID: 29155147
5-Amino-1MQ reversed diet-induced obesity in mice within 11 days at 20 mg/kg without reducing food intake; confirmed concentration-dependent NNMT inhibition in adipocytes.
- 2.
Kannt A, et al. A small molecule inhibitor of Nicotinamide N-methyltransferase for the treatment of metabolic disorders. Scientific Reports. 2018.PMID: 29483571
NNMTi combined with low-fat diet produced dramatic whole-body adiposity reduction and metabolic normalization in obese mice.
5-Amino-1MQ
Metabolic Research
Purgo Labs list price, read 12 Sep 2026 · per-lot COA on the vendor page
50mg $99.99 → $79.99 with code HEALTH (20% off; price read 2 Oct 2026)
- 1 certificate verified at the lab50mg$99.99→ $79.99
Fast FedEx shipping · Discreet packaging
Technical Specifications
| Compound Name | 5-Amino-1MQ (5-amino-1-methylquinolinium) |
| Molecular Formula | C10H10N2 |
| Molecular Weight | 174.20 Da |
| Compound Class | Small molecule NNMT inhibitor (not a peptide) |
| Primary Target | Nicotinamide N-methyltransferase (NNMT) |
| Downstream Effects | NAD+ preservation, SIRT1 activation, adipogenesis inhibition |
| Regulatory Status | Research chemical; not FDA-approved |
| Form | Lyophilized powder |
| Purity | ≥99% (third-party tested) |
Source 5-Amino-1MQ at Purgo Labs
50mg $99.99 list · $79.99 with code HEALTH · lab-verifiable COA per lot
Other Compounds in This Guide
Supporting Research
5-Amino-1MQ is a small molecule NNMT inhibitor studied preclinically in mouse models for obesity and metabolic syndrome. No human clinical trials have been conducted.
References
- Neelakantan H, et al.PRECLINICAL — mouseBiochemical Pharmacology. 2018. PubMed5-Amino-1MQ (NNMT inhibitor) reduced adiposity and improved metabolic parameters in high-fat diet mouse models; no human data.
- Kannt A, Pfenninger A.REVIEWReview of NNMT as a therapeutic target for metabolic disease; notes preclinical-only evidence base and absence of human clinical data.
Research Databases
Ready to Source 5-Amino-1MQ?
Purgo Labs offers 5-Amino-1MQ with ≥99% purity, third-party certificates of analysis, and fast FedEx shipping. This is an affiliate link — we may earn a commission at no cost to you.